Inflammatory cytokine release in keratinocyte

The term "inflammatory cytokine release in keratinocyte" describes a process by which keratinocytes, the predominant cells of the epidermis, produce and secrete a broad array of proinflammatory cytokines and chemokines in response to various stimuli such as mechanical stress, infection, trauma, or immune signaling(2)[2][3][4][6]. This cytokine output includes, but is not limited to, interleukins (IL-1α, IL-6, IL-8, IL-18, IL-33, IL-36), TNF-α, TSLP, CCL27, and CXCL10(2)[2][4][6]. Keratinocyte-derived cytokines amplify inflammatory responses, induce keratinocyte proliferation and differentiation, promote leukocyte recruitment, and drive the pathogenesis of several skin diseases, especially psoriasis and atopic dermatitis(2)[2][3][5][6]. This process forms a self-reinforcing inflammatory loop with immune cells, resulting in chronic skin inflammation when dysregulated(3)[3][5]. Clinically, drugs targeting specific cytokines or their receptors (e.g., IL-33, TSLP, CTLA4-Ig) have been investigated; however, cytokine signaling in keratinocytes should not be considered a single molecular entity or direct drug target, but rather a complex immune process involving multiple molecular players[4][5][6]. Thus, "inflammatory cytokine release in keratinocytes" describes a biological phenomenon, not a specific target molecule, enzyme, receptor, or protein. Rationale for 'is_incorrect': This entry is not a canonical molecule, receptor, or therapeutic target but a complex cellular process. No single standardized protein or receptor with this name exists; instead, keratinocyte cytokine release involves many molecular targets and signaling pathways[2][3][4][6]. If you wish to catalog or target a specific cytokine, receptor, or pathway (for example, TLR2, IL-33, or TSLP receptor), those should be listed under their proper canonical names.

Other names

Proinflammatory cytokine secretion by keratinocyteCytokine signaling in keratinocyteKeratinocyte immune activation

Blockade of T-lymphocyte co-stimulation (CTLA4-Ig), Suppression of inflammatory cytokine or chemokine signaling, Antagonism of cytokine receptors (anti-IL-33, anti-ST2), Downregulation of chemokine pathways